In this video interview, Michael Daines, MD, explains phase 3 data for Panzyga (Octapharma) for pediatric acute- onset neuropsychiatric syndrome (PANS).
Michael O. Daines, MD, division chief of Pediatric Allergy and Immunology at the University of Arizona College of Medicine and principal investigator of the phase 3 trial evaluating Panzyga for pediatric acute-onset neuropsychiatric syndrome (PANS), emphasized the potential clinical benefit of the treatment despite narrowly missing its primary efficacy endpoint in a recent phase 3 study.
"We chose a primary endpoint of something called a CY-BOCS, which is a validated scoring system for looking at OCD," said Daines. "There was a clinically relevant improvement in children that were treated with Panzyga in this study, but it did not reach statistical significance, because there was also some improvement in the placebo."
The randomized, double-blind, placebo-controlled trial assessed the safety and efficacy of Panzyga (immune globulin intravenous, human – ifas) 10% in 71 pediatric patients aged 6 to 17 years with moderate-to-severe PANS. Participants received 3 infusions of Panzyga or placebo over 2 days every 3 weeks for a total of 9 weeks, followed by a double-blind, crossover extension period.
While CY-BOCS (Children's Yale-Brown Obsessive-Compulsive Scale) was selected as the primary endpoint because of the central role OCD symptoms play in diagnosing PANS, the improvement observed in the Panzyga group, though greater than in placebo, did not achieve statistical significance (P = 0.072).
"Many times in clinical studies, when you start bringing kids in and observing them and looking at them and doing things with them, they get better just from being part of a clinical study," Daines noted.
However, the trial's secondary endpoint—the Clinical Global Impression-Improvement (CGI-I) scale—showed a statistically and clinically significant improvement (P = 0.017).
"This is a broader tool that looks at essentially how sick the child is," said Daines. "It’s also going to include those minor criteria… and there was a clinically relevant and strongly significant improvement in the CGI in the children that were receiving treatment."
Looking ahead, Daines highlighted the need for continued research, and pointed to the need for studies of other immune-modulatory treatments that may offer lower costs or improved safety, as well as the importance of identifying a biomarker for more efficient diagnosis.
"There are a lot of diseases that don't have biomarkers… but because it is a relatively complex assessment… if we had a simple blood test or microbiome test… that could help us get to a diagnosis quicker," he added.
Reference:
Octapharma releases results for phase 3 superiority study of pediatric acuteonset neuropsychiatric syndrome. Octapharma. Press release. May 27, 2025. Accessed June 19, 2025. https://www.octapharma.com/news/press-release/2025/octapharma-releases-results-phase3-superiority-study-pediatric-acuteonset-neuropsychiatric-syndrome
Addictive screen use tied to youth mental health risks
Addictive use of screens—not total time—was linked to higher risks of suicidal behavior and mental health issues in early adolescents.
Addressing atypical anorexia: Part 3
The final episode in our podcast series on atypical anorexia discusses fat bias in health care and its impact on diagnosis and when pushback against diagnosis happens.
Phase 3 trial of omaveloxolone to treat Friedreich ataxia in children aged 2 to <16 begins
Currently, omaveloxolone (Skyclarys) is approved to treat adults and adolescents aged 16 years and older impacted by FA.
Addressing atypical anorexia: Part 2
Dr. Erin Harrop discusses the necessity of understanding that eating disorders do not all look the same in every patient and how a multidisciplinary approach could be an effective way to diagnose and manage anorexia nervosa that is atypical.
Rise in pediatric firearm deaths linked to permissive state gun laws
New research highlights how differences in state laws may be linked to changing trends in pediatric firearm mortality across the United States.
Study: Even low lead exposure in early childhood tied to academic decline
Children with blood lead levels below CDC intervention thresholds had lower test scores through adolescence, a new study showed.
Addictive screen use tied to youth mental health risks
Addictive use of screens—not total time—was linked to higher risks of suicidal behavior and mental health issues in early adolescents.
Addressing atypical anorexia: Part 3
The final episode in our podcast series on atypical anorexia discusses fat bias in health care and its impact on diagnosis and when pushback against diagnosis happens.
Phase 3 trial of omaveloxolone to treat Friedreich ataxia in children aged 2 to <16 begins
Currently, omaveloxolone (Skyclarys) is approved to treat adults and adolescents aged 16 years and older impacted by FA.
Addressing atypical anorexia: Part 2
Dr. Erin Harrop discusses the necessity of understanding that eating disorders do not all look the same in every patient and how a multidisciplinary approach could be an effective way to diagnose and manage anorexia nervosa that is atypical.
Rise in pediatric firearm deaths linked to permissive state gun laws
New research highlights how differences in state laws may be linked to changing trends in pediatric firearm mortality across the United States.
Study: Even low lead exposure in early childhood tied to academic decline
Children with blood lead levels below CDC intervention thresholds had lower test scores through adolescence, a new study showed.
2 Commerce Drive
Cranbury, NJ 08512
609-716-7777
